Columbus, Ohio 43221


Purpose:

The purpose of this study is to assess whether the MMF07 Foot Massager and/ or heat therapy may improve symptoms of restless legs syndrome (RLS). It will also assess the effect of the MMF07 Foot Massager and/ or heat on quality of life and sleep in people affected by RLS. Participants will be randomly assigned to one of four treatment groups; 1. MMF07 Foot Massager device 2. Heat therapy 3. Heat therapy and the MMF07 Foot Massage device 4. Neither heat nor MMF07 Foot Massager device (no treatment group)


Study summary:

Few clinical trials have looked into non-pharmacological, non-invasive treatments for restless legs syndrome, despite reports that massage, baths and vibrations can alleviate RLS symptoms. We would like to assess whether the MMF007 Foot Massager device and/or heat therapy is associated with improved severity of RLS symptoms. For this study the investigator will enroll 40 participants who have been diagnosed with restless legs syndrome, who will be followed over the course of four weeks and asked to complete two in person study visits. In the study the investigator is comparing the use of the MMF007 Foot Massager device and/ or heat therapy to a non treatment group to assess if the symptoms of RLS improve.


Criteria:

Inclusion Criteria: 1. Subjects between 18-75 years old diagnosed with RLS according to the diagnostic criteria of the International Restless Legs Syndrome Study Group (11) 2. Subjects should have bothersome RLS symptoms, despite best medical therapy 3. Subjects should be stable on all RLS medication for at least 4 weeks prior to enrollment 4. All subjects must have vision and be proficient in English for compliance with testing and surveys 5. All women of childbearing age must be using an acceptable form of birth control, including abstinence, intrauterine device (IUD) or intrauterine system in place for at least 3 months prior to screening, subject or partner using barrier method (e.g., condom, diaphragm, or cervical cap) with spermicide from screening through study completion; partner has a documented vasectomy > 6 months prior to Baseline, Stable hormonal contraception (with approved oral, transdermal, or depot regimen) for at least 3 months prior to screening Exclusion Criteria: 1. RLS secondary associated with end stage renal disease, iron deficiency or pregnancy 2. Concomitant sleep disorders 3. Any other condition (other than the primary indications), which in the opinion of the investigators might contribute to difficulty complying with the protocol


NCT ID:

NCT02526277


Primary Contact:

Kate Ambrogi
Phone: 614-688-6685
Email: katherine.ambrogi@osumc.edu


Backup Contact:

N/A


Location Contact:

Columbus, Ohio 43221
United States

Kate Ambrogi
Phone: 614-688-6685
Email: katherine.ambrogi@osumc.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: November 24, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.